These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29074595)

  • 21. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
    Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
    Chang L; Duan MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 24. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
    Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
    Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
    Greenfield G; McPherson S; Mills K; McMullin MF
    J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
    Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ;
    J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
    Sankar K; Stein BL
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1539-1545. PubMed ID: 30545998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
    Verstovsek S; Harrison CN; Kiladjian JJ; Miller C; Naim AB; Paranagama DC; Habr D; Vannucchi AM
    Leuk Res; 2017 May; 56():52-59. PubMed ID: 28193568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
    Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T
    Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
    Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
    Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.
    Masciulli A; Ferrari A; Carobbio A; Ghirardi A; Barbui T
    Blood Adv; 2020 Jan; 4(2):380-386. PubMed ID: 31985808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib for the Treatment of Essential Thrombocythemia.
    Gunawan A; Harrington P; Garcia-Curto N; McLornan D; Radia D; Harrison C
    Hemasphere; 2018 Aug; 2(4):e56. PubMed ID: 31723782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
    Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
    Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.